OTOkan Tanriverdi

Okan Tanriverdi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Okan Tanriverdi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Application of Artificial Intelligence in the Field of Cardiovascular Diseases Focuses on Both Diagnostic and Therapeutic Aspects.

    by Lütfü Aşkın, Esra Polat, Yusuf Hoşoğlu, Okan Tanrıverdi

    Artificial intelligence (AI) is used in the field of medicine to retrieve information from large databases by using advanced computer algorithms. AI has the potential to accelerate the identification and management of cardiovascular diseases (CVDs), including conditions such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and several others. From a clinical perspective, AI enhances the diagnosis of CVD, increases the usefulness of auxiliary tools, aids in stratifying and identifying different types of diseases, and enables accurate prediction of outcomes. State-of-the-art AI algorithms, designed to extract minute connections from extensive healthcare data, are anticipated to address more challenging tasks compared to earlier methods. The goal of this research is to emphasize the current uses of AI in CVDs, thereby equipping doctors with little knowledge in computer science to gain a deeper understanding and effectively use AI algorithms in clinical practice.


  • Myocardial performance index and cardiovascular diseases

    by Lutfu Askin, Elif İlKay Yuce, Okan Tanriverdi

    The Myocardial Performance Index (MPI), also known as the Tei Index, is a measure of the overall performance of the heart that takes into account both systolic and diastolic function. It is a non‐invasive echocardiographic index that provides information about the efficiency of the heart's pumping action. The MPI is a useful tool for evaluating cardiac function in various clinical conditions, such as heart failure, myocardial infarction, and cardiomyopathy. A higher MPI value indicates poorer cardiac function, while a lower MPI value indicates better cardiac function. This review will give a summary of the relevant MPI literature, provide a methodology and technical aspects, and make research recommendations.


  • Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships

    by Lutfu Askin, Sabri Abus, Okan Tanriverdi

    : Serum resistin, mainly secreted by the bone marrow, monocytes, and macrophages, contributes to many processes, including endothelial dysfunction, Vascular Smooth Muscle Cell (VSMC) proliferation, and atherothrombosis demonstrating effects on the development of hypertension and Coronary Artery Disease (CAD). Previously published clinical studies have shown that plasma resistin levels are significantly associated with cardiovascular disease risk factors and adverse clinical outcomes associated with the condition. Resistin is associated with vascular smooth muscle cell dysfunction in vitro, most plausibly due to its relationship with oxidative stress in advanced atherosclerosis whereas in vivo studies have shown resistin to be associated with intimal hyperplasia. We aimed to summarize the role of resistin on cardiovascular disease (CVD), as we could not find any review focused on the role of resistin on CVD.


  • Open Access

    Association between Omentin-1 and Coronary Artery Disease: Pathogenesis and Clinical Research

    by Lutfu Askin, Hakan Duman, Ali Ozyıldız, Okan Tanriverdi, Serdar Turkmen

    : Like other adipokines, omentin-1 is secreted from visceral adipose tissue and plays a vital role in the development of chronic inflammatory diseases, including cardiovascular events. Recent studies have shown that circulating omentin-1 levels are associated with various metabolic risk factors, such as high blood pressure, increased waist circumference, dyslipidemia, and glucose intolerance. The decrease in serum omentin level is an independent predictor of Coronary Artery Disease (CAD) and is associated with the severity of this disease. Since there is no relevant review in the literature, we aimed to summarize the studies on the relationship between omentin-1 and CAD.